MedImmune Appoints Development Leadership Team
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Cambridge Antibody Technology exec to oversee product development.
You may also be interested in...
AstraZeneca Concentrates Biologics At MedImmune, Ups R&D
MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.
AstraZeneca Hears CAT’s Meow With Biotech Acquisition
Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: